ADT + apalutamide (continuous)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-LEUPROLIDE DRUG-APALUTAMIDE |
|---|
| ID | REG-ADT-APALUTAMIDE |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Notes
TITAN: mHSPC benefit. SPARTAN: nmCRPC benefit. Distinguishing AE: rash (~24%); hypothyroidism (~8%) — monitor TSH. Less CNS penetration than enzalutamide.
Used By
No reverse references found in the YAML corpus.